Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Cell - 10 Aug 2017

Horwitz Joshua A, Bar-On Yotam, Lu Ching-Lan, Fera Daniela, Lockhart Ainsley A K, Lorenzi Julio C C, Nogueira Lilian, Golijanin Jovana, Scheid Johannes F, Seaman Michael S, Gazumyan Anna, Zolla-Pazner Susan, Nussenzweig Michel C

Abstract excerpt

Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial. To investigate the role of nnAbs on HIV-1 infection in vivo, we devised a replication-competent HIV-1 reporter virus that expresses a heterologous HA-tag on the surface of infected cells and virions. Anti-HA antibodies bind to,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AIDS Vaccines
Share to CD4 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Antibodies

Share to HIV Envelope Protein gp120

Share to HIV Infections

Share to Receptors, Fc

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 28757252
DOI: 10.1016/j.cell.2017.06.048
PMCID: PMC5554461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.PMID 28757252Read ↗

Harnessing the protective potential of HIV-1 neutralizing antibodiesSemantic proximity Read ↗

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and PreventionSemantic proximity Read ↗

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized miceSemantic proximity Read ↗

Next-generation bNAbs for HIV-1 cure strategiesSemantic proximity Read ↗

Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 AntibodiesSemantic proximity Read ↗

Progress toward active or passive HIV-1 vaccination.Semantic proximity Read ↗

Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine StrategySemantic proximity Read ↗

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapySemantic proximity Read ↗

Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availabilitySemantic proximity Read ↗

HIV-1 Vpu restricts Fc-mediated effector functions in vivoSemantic proximity Read ↗

Broad Neutralization of Human Immunodeficiency Virus Type 1 (HIV-1) Elicited from Human Rhinoviruses That Display the HIV-1 gp41 ELDKWA EpitopeSemantic proximity Read ↗

Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.